NYSE:APUS | Cash Flow Statement | Apimeds Pharmaceuticals US, Inc.

Complete source-backed cash-flow history.

Available history
2023-12-31 to 2026-06-30
Data captured

Historical Cash Flow Statement

DateNet incomeDepreciation and amortizationOperating cash flowCapital expenditureInvesting cash flowShare repurchasesDividends paidFinancing cash flow
2026-06-30-$20.17M
2026-03-31-$35.06M-$2.07M$9,394.00$490,606.00$920,000.00
2025-12-31-$1.16M-$3.82M$21,424.00-$10.02M$8.49M
2025-09-30-$1.78M
2025-06-30-$2.66M
2025-03-31-$402,397.00-$20,313.00$267,200.00
2024-12-31-$311,633.00-$99,616.00$76,500.00
2024-09-30-$332,521.00
2024-06-30-$449,363.00
2024-03-31-$296,473.00-$263,100.00

Annual Cash Flow Statement

DateNet incomeDepreciation and amortizationOperating cash flowCapital expenditureInvesting cash flowShare repurchasesDividends paidFinancing cash flow
2025-12-31-$6M-$8.93M$57,333.00-$10.06M$20.62M
2024-12-31-$1.39M-$733,526.00$326,500.00
2023-12-31-$777,694.00-$627,790.00$1.03M